Connor, Clark & Lunn Investment Management (CC&L)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-145,736	Closed	-$717K	–	1742
2024 Q1	$717K	Buy	145,736 +113,348	+350%	+$671K	﹤0.01%	995
2023 Q4	$285K	Buy	+32,388	New	+$265K	﹤0.01%	1187
2023 Q3	–	Sell	-44,001	Closed	-$1.11M	–	1580
2023 Q2	$1.11M	Sell	44,001 -87,451	-67%	-$2.72M	0.01%	763
2023 Q1	$4.23M	Buy	+131,452	New	+$4.1M	0.02%	401

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RVNC Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 145,736 shares — an estimated $717K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RVNC in Q1 2023 and held it in 4 quarters. The position peaked at $4.23M in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 145,736 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $717K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 4 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Revance Therapeutics, Inc. position peaked at $4.23M in Q1 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.